Data Could Make Roche Drug a Hemophilia Standard, But for How Long?

It’s been a bumpy ride for emicizumab (Hemlibra) in 2018. The Roche/Genentech drug, approved by the FDA in late 2017, has a chance to become the choice treatment for people with hemophilia A, an…
Read the full story: Xconomy